Reversal of Peripheral Iris Depigmentation Associated with Vogt-Koyanagi-Harada Disease

References

• Gocho K, Kondo I, Yamaki K. Identification of autoreactive T cells in Vogt-Koyanagi-Harada disease. Invest Ophthalmol Vis Sci. 2001;42:2004–2009.
   PubMed Web of Science ®Google Scholar
• Yamaki K, Gocho K, Hayakawa K, Kondo I, Sakuragi S. Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease. J Immunol. 2000;165(12):7323–7329. doi:10.4049/jimmunol.165.12.7323.
   PubMed Web of Science ®Google Scholar
• Yamaki K, Kondo I, Nakamura H, Miyano M, Konno S, Sakuragi S. Ocular and extraocular inflammation induced by immunization of tyrosinase related protein 1 and 2 in lewis rats. Exp Eye Res. 2000;71(4):361–369. doi:10.1006/exer.2000.0893.
   PubMed Web of Science ®Google Scholar
• Fang W, Yang P. Vogt-Koyanagi-Harada syndrome. Curr Eye Res. 2008;33(7):517–523. doi:10.1080/02713680802233968.
   PubMed Web of Science ®Google Scholar
• Yang P, Ren Y, Li B, Fang W, Meng Q, Kijlstra A. Clinical characteristics of Vogt-Koyanagi-Harada syndrome in Chinese patients. Ophthalmology. 2007;114(3):606–614. doi:10.1016/j.ophtha.2006.07.040.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Al Tamimi M, Hemachandran S, Al-Mezaine HS, Al-Muammar A, Kangave D. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids. Acta Ophthalmol. 2019;91(6):e486–e493. doi:10.1111/aos.12127.
   Google Scholar
• Park YJ, Park KH, Woo SJ. Clinical features of pregnancy-associated retinal and choroidal diseases causing acute visual disturbance. Korean J Ophthalmol. August, 2017 31(4):320–327. doi:10.3341/kjo.2016.0080.
   PubMedGoogle Scholar
• Sonia A, Zaouali S, Bettaieb A, Ben Yahia S, Khairallah M. Peripheral iris depigmentation and ocular hypotony: result of the natural course of non-treated Vogt-Koyanagi-Harada (VKH) disease. Int Ophthalmol. 2007;27(2–3):221–222. doi:10.1007/s10792-007-9048-7.
   PubMedGoogle Scholar
• Chee SP, Win MZA. Iris manifestations in inadequately treated chronic recurrent Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2021. doi:10.1080/09273948.2020.1870701.
   Web of Science ®Google Scholar
• Cuevas M, De-la-torre A, Córdoba A. Bilateral iris depigmentation and ocular hypotony as end-stage manifestations of untreated Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. 2018;26(7):1101–1106. doi:10.1080/09273948.2017.1320411.
   PubMed Web of Science ®Google Scholar
• Saari JM, Nummelin K. Iris atrophy, serous detachment of the ciliary body, and ocular hypotony in chronic phase of Vogt-Koyanagi-Harada disease. Eur J Ophthalmol. 2055;15(2):277–283. doi:10.1177/112067210501500218.
   Google Scholar
• Suhler Eric B. Symmetric peripheral iris depigmentation in Vogt-Koyanagi-Harada syndrome. Arch Ophthalmol. 2002;120(8):1104. doi:10.1001/archopht.120.8.1104.
   PubMedGoogle Scholar
• Abu El-Asrar AM, Dheyab A, Khatib D, Struyf S, Van Damme J, Opdenakker G. Efficacy of B cell depletion therapy with rituximab in refractory chronic recurrent uveitis associated with Vogt-Koyanagi-Harada disease. Ocul Immunol Inflamm. April 3, 2022 30(3);750–757. doi:10.1080/09273948.2020.1820531. Epub September 29, 2020. PMID: 32990482.
   PubMed Web of Science ®Google Scholar
• Abu El-Asrar AM, Struyf S, Van den Broeck C, et al. Expression of chemokines and gelatinase B in sympathetic ophthalmia. Eye. 2007;21:649–657. doi:10.1038/sj.eye.6702342.
   PubMed Web of Science ®Google Scholar
• Streilein JW. Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nat Rev Immunol. November, 2003 3(11):879–889. doi:10.1038/nri1224. PMID: 14668804.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Araz B, Taskapili M, et al. Bilateral acute depigmentation of the iris: report of 26 new cases and four-year follow-up of two patients. Ophthalmology. 2009;116(8):1552–1557. doi:10.1016/j.ophtha.2009.02.019.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Onal, S, Garip, A, et al. Bilateral acute iris transillumination. Arch Ophthalmol. 2011;129(10):1312–1319. doi:10.1001/archophthalmol.2011.310.
   PubMedGoogle Scholar
• Tabbara KF. Reversal of poliosis and vitiligo following Vogt-Koyanagi-Harada disease. Arch Ophthalmol. March, 2012 130(3):394–396. doi:10.1001/archopthalmol.2011.1520. PMID: 22411673.
   PubMedGoogle Scholar
• Subudhi P, Khan Z, Subudhi BNR, Sitaram S. Unusual case of vitiligo reversal in Vogt-Koyanagi-Harada syndrome. Indian J Ophthalmol. September, 2017 65(9):867–868. doi:10.4103/ijo.IJO_336_17. PMID: 28905833; PMCID: PMC5621272.
   PubMed Web of Science ®Google Scholar
• Lim JA, Tan WC, Nor NM. Hints from the skin beneath: vitiligo in Vogt–Koyanagi–Harada disease. Dermatol Sin. 2022;40:78. doi:10.4103/DS.DS_23_22.
   Web of Science ®Google Scholar
• Dolz-Marco R, Gallego-Pinazo R, Díaz-Llopis M. Rituximab in refractory Vogt-Koyanagi-Harada disease. J Ophthalmic Inflamm Infect. December, 2011 1(4):177–180. doi:10.1007/s12348-011-0027-9. Epub July 9, 2011 PMID: 21744181; PMCID: PMC3223341.
   PubMedGoogle Scholar
• Caso F, Rigante D, Vitale A, et al. Long-lasting uveitis remission and hearing loss recovery after rituximab in Vogt-Koyanagi-Harada disease. Clin Rheumatol. October, 2015 34(10):1817–1820. doi:10.1007/s10067-014-2781-1. Epub September 16, 2014 PMID: 25224382.
   PubMed Web of Science ®Google Scholar
• Umran RMR, Shukur ZYH. Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease. Mod Rheumatol. January, 2018 28(1):197–199. doi:10.3109/14397595.2015.1071234. Epub August 18, 2015 18. PMID: 26154298.
   PubMed Web of Science ®Google Scholar
• AlBloushi AF, AlEnezi SH, Al Owaifeer AM, Al-Hadlaq OS, Gikandi PW, Abu El-Asrar AM. Long-term outcomes of uveitis associated with Vogt-Koyanagi-Harada disease in the pediatric age group. Ocul Immunol Inflamm. June, 2021 ;29:1–9. doi:10.1080/09273948.2021.1933074.
   PubMedGoogle Scholar